GERMANTOWN, Md., March 5,
2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq:
PGEN), a biopharmaceutical company specializing in the development
of innovative gene and cell therapies to improve the lives of
patients, today announced the Company will report fourth
quarter and full year 2023 financial results on Tuesday, March 19, 2024. The Company will host a
conference call that day at 4:30 PM
ET to discuss financial results and provide a general
business update.
The conference call may be accessed by dialing 1-888-664-6383
(North America) or 1-416-764-8650
(International) to join the Precigen Conference Call. Participants
are asked to dial in 10-15 minutes in advance of the scheduled call
time to facilitate timely connection to the call.
Participants may view details for the event through Precigen's
website in the Events & Presentations section at
investors.precigen.com/events-presentations.
Precigen: Advancing Medicine with
Precision™
Precigen (Nasdaq: PGEN) is a dedicated
discovery and clinical stage biopharmaceutical company advancing
the next generation of gene and cell therapies using precision
technology to target the most urgent and intractable diseases in
our core therapeutic areas of immuno-oncology, autoimmune
disorders, and infectious diseases. Our technologies enable us to
find innovative solutions for affordable biotherapeutics in a
controlled manner. Precigen operates as an innovation engine
progressing a preclinical and clinical pipeline of
well-differentiated therapies toward clinical proof-of-concept and
commercialization. For more information about Precigen, visit
www.precigen.com or follow us on X @Precigen, LinkedIn or
YouTube.
Cautionary Statement Regarding Forward-Looking
Statements
Some of the statements made in this press release
are forward-looking statements. These forward-looking statements
are based upon the Company's current expectations and projections
about future events and generally relate to plans, objectives, and
expectations for the development of the Company's business,
including the timing and progress of preclinical studies, clinical
trials, discovery programs, product candidate approval and
commercialization and related milestones, the promise of the
Company's portfolio of therapies, and in particular its CAR-T and
AdenoVerse therapies. Although management believes that the plans
and objectives reflected in or suggested by these forward-looking
statements are reasonable, all forward-looking statements involve
risks and uncertainties and actual future results may be materially
different from the plans, objectives and expectations expressed in
this press release. The Company has no obligation to provide any
updates to these forward-looking statements even if its
expectations change. All forward-looking statements are expressly
qualified in their entirety by this cautionary statement. For
further information on potential risks and uncertainties, and other
important factors, any of which could cause the Company's actual
results to differ from those contained in the forward-looking
statements, see the section entitled "Risk Factors" in the
Company's most recent Annual Report on Form 10-K and subsequent
reports filed with the Securities and Exchange Commission.
Investor Contact:
Steven M.
Harasym
Vice President, Investor Relations
Tel: +1 (301) 556-9850
investors@precigen.com
Media Contacts:
Donelle M.
Gregory
press@precigen.com
Glenn Silver
Lazar-FINN Partners
glenn.silver@finnpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/precigen-to-announce-fourth-quarter-and-full-year-2023-financial-results-on-march-19th-302079191.html
SOURCE Precigen, Inc.